Ensysce Biosciences, Inc.
ENSC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,210 | $2,231 | $2,523 | $3,531 |
| % Growth | 133.5% | -11.6% | -28.5% | – |
| Cost of Goods Sold | $7,219 | $7,587 | $19,836 | $0 |
| Gross Profit | -$2,009 | -$5,357 | -$17,312 | $3,531 |
| % Margin | -38.6% | -240.1% | -686.1% | 100% |
| R&D Expenses | $7,219 | $7,587 | $19,836 | $4,690 |
| G&A Expenses | $4,721 | $5,361 | $6,910 | $0 |
| SG&A Expenses | $4,721 | $5,361 | $6,910 | $18,711 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$7,219 | -$7,587 | -$19,836 | $0 |
| Operating Expenses | $4,721 | $5,361 | $6,910 | $23,401 |
| Operating Income | -$6,730 | -$10,718 | -$24,222 | -$19,870 |
| % Margin | -129.2% | -480.4% | -959.9% | -562.7% |
| Other Income/Exp. Net | -$1,257 | $92 | $14 | -$9,275 |
| Pre-Tax Income | -$7,987 | -$10,626 | -$24,208 | -$29,146 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,987 | -$10,613 | -$24,172 | -$29,084 |
| % Margin | -153.3% | -475.7% | -957.9% | -823.6% |
| EPS | -4.57 | -4.69 | -139.44 | -355.68 |
| % Growth | 2.6% | 96.6% | 60.8% | – |
| EPS Diluted | -4.57 | -4.69 | -139.44 | -355.68 |
| Weighted Avg Shares Out | 1,747 | 2,264 | 180 | 84 |
| Weighted Avg Shares Out Dil | 1,747 | 2,264 | 180 | 84 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1,247 | $3,215 |
| Interest Expense | $1,290 | $354 | $110 | $1,295 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$6,730 | -$10,718 | -$24,222 | -$25,930 |
| % Margin | -129.2% | -480.4% | -959.9% | -734.3% |